|
- Incyte - Biopharmaceutical Company | Solutions for Unmet Medical Needs . . .
Incyte is a global biopharmaceutical company focused on finding innovative solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines
- Global Biopharmaceutical Company | Incyte. com
Incyte is a global biopharmaceutical company that has created a robust and diversified portfolio of marketed products and clinical candidates in oncology and inflammation and autoimmunity
- Portfolio: MPNs GVHD, Hematology Oncology, Dermatology . . . - Incyte
Incyte supports significant independent research aimed at enhancing disease understanding and advancing the study of our products by generating health outcomes data and real-world evidence
- Our Leadership - Incyte
Meet Incyte’s executive management team of accomplished experts led by Chairman, President and CEO Hervé Hoppenot
- Drug Development Scientific Innovation in Oncology and . . . - Incyte
Incyte’s team of biologists and chemists are pursuing new areas in drug discovery and development in order to help patients
- Oncology Research | Targeted Immunotherapy For Cancer - Incyte
Incyte is focused delivering medicines that may offer patients with cancer new options in treatment by addressing tumors from multiple directions with targeted and immunotherapies
- Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it . . .
"The FDA approval of Zynyz marks a pivotal moment, bringing effective combination and monotherapy treatment options to patients with advanced anal cancer after decades of limited innovation," said Hervé Hoppenot, Chief Executive Officer, Incyte "At Incyte, we focus our efforts where we can make the biggest impact for patients
- Incyte Portfolio May 21, 2025
Please refer to local prescribing information for more information, including full safety information, on Incyte’s marketed medicines, or on medicines marketed by Incyte’s collaboration partners
|
|
|